Multinational biotech CSL [ASX:CSL] released its half-year 2023 results to the markets earlier on Tuesday. The company revealed its net profit after tax had reached $1.62 billion — 7% less than last year. However, this was impacted by one-off costs associated with the major acquisition of Vifor Pharma.
The biotech says Vifor lends a 15% uptick in revenue growth and has reaffirmed its existing guidance, which is expected to balance out with no further costs linked to Vifor to consider.
Today the group’s share price was lifted slightly from its last closing price, worth $308.84 at the time of writing.
CSL has moved strongly over the 12 months, going up 27%.
Source: tradingview.com
Revenue raises for CSL in the second half 2023
Today the biotech reported $1.62 billion in net profit after tax for the first half of the fiscal 2023 year. It was a 7% decrease on the profit earned a year before. However, this does include one-off costs that were incurred through its acquisition of Vifor Pharma.
CSL’s underlying profit came to a total of $1.82 billion, a 10% increase on the period before on a constant currency basis.
Revenue raised 19% to $US7.2 billion, boosted by strong growth in CSL’s most popular products.
With Vifor added to the company’s ranks and contributing to five months of earnings in the first half, the company can now incorporate a further 15% in revenue growth, with integration already underway and cost synergies also on track.
The group reported NPATA (net profit after tax) earnings per share of $3.77 and interim dividends of US$1.07 per share (AU$1.55 a share and a boost of 9%).
CSL said there was strong growth in immunoglobulin and albumin sales (US$2.227 and $585 million, respectively), and the company hit new record levels in plasma collections (up 36%).
There was found to be strong growth in the market for its haemophilia B product IDELVION and KCENTRA as well as influenza vaccine CSL Seqirus, which brought in US$1.738 billion, an increase of 9% in sales.
CSL has secured a licence agreement for its mRNA vaccine technology, and the FDA has approved HEMGENIUX.
Mr Paul Perreault, CSL’s CEO who is soon to be replaced by COO Paul McKenzie, commented:
‘CSL delivered a solid performance in the first half of the financial year demonstrating the strong fundamentals of the company and the disciplined execution of our patient focused strategy.
‘Our focused investment across our business units underpinned our resilience throughout the pandemic, and as we emerge from it we are starting to deliver positive momentum behind our sustainable growth agenda.’
The group believes plasma collections will continue to grow and immunoglobulins will continue strong.
HEMGENIX is due to launch in the US, Seqirus is expected to deliver another profitable year, and CSL will be able to take full advantage of Vifor going forward.
CSL has reaffirmed its guidance for FY23, with 28–30% growth in revenue expected and 13–18% growth in NPATA.
Booming Australian commodities
It’s a busy time in the commodities market, and things are only just heating up.
Our in-house resources expert and trained geologist, James Cooper, thinks the Australian resources sector is set to enter a new commodities boom brought on by the ‘Age of Scarcity’.
James is convinced ‘the gears are in motion for another multi-year boom in commodities’… and better yet, this is a boom where Australia and its stocks stand to benefit greatly.
The next big mining boom is predicted to happen in the next few years. The question is, are you ready for it?
Don’t let the same people who got rich last time be the only ones for a second time!
You can access a recent report by James on exactly that topic, AND access an exclusive video on his personalised ‘attack plan’ — right here.
Regards,
Mahlia Stewart
For The Daily Reckoning
